Ollin presents head-to-head OLN324 vs. Vabysmo data at ASRS ahead of Phase 3
The Phase 1b JADE readout, already disclosed in March, gets an oral presentation on anatomic and vision outcomes as Ollin heads toward Phase 3 trials in DME and wet AMD.
Executive Summary
- Ollin Biosciences is presenting a head-to-head Phase 1b comparison of OLN324 against faricimab in two retinal diseases at a major specialist meeting, putting previously announced trial results in front of practicing retina physicians for the first time.
- The trial reported anatomic improvements that came faster and were larger with OLN324 than with faricimab, alongside a favorable safety readout and fewer patients needing retreatment.
- The company is using this dataset as the stated basis for starting global Phase 3 trials later this year, so how retina specialists react to the design and results shapes expectations for that program.
- Faricimab and aflibercept dominate the approved treatment landscape for both indications, and OLN324 has no other VEGF/Ang2 bispecific in Phase 1 or later development sharing its exact mechanism in this dataset.
The presentation
Ollin Biosciences, Inc. will deliver two oral presentations at the ASRS 44th Annual Scientific Meeting in Montreal on July 16, 2026, one covering wet age-related macular degeneration (wAMD) at 8:15 a.m. EDT presented by David Eichenbaum, M.D., and one covering diabetic macular edema (DME) at 2:04 p.m. EDT presented by Veeral Sheth, M.D.. Both cover the randomized, head-to-head Phase 1b JADE study (NCT07484074) comparing intravitreal OLN324 to faricimab (Vabysmo). The trial enrolled 164 patients across sites in the United States and Puerto Rico, completed in October 2025, and closed out with a Completed status by March 2026. Ollin+1Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Scientific MeetingJul 13, 2026A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324NCT07484074
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The data behind it
Ollin first disclosed final Week 20 results from JADE in late March 2026: OLN324 showed zero cases of intraocular inflammation compared with one case for faricimab, a mean vision gain of 2.2 letters in wAMD, roughly 50% greater reductions in pigment epithelial detachment thickness at Week 12, and higher rates of remaining retreatment-free through 12 weeks off treatment. The registered primary endpoint of the study is adverse events, measured through Weeks 12 and 20, consistent with a Phase 1b design built to establish safety and tolerability rather than to power a formal efficacy comparison. The July 13, 2026 release describing the ASRS sessions again characterizes the anatomic differences as faster and greater than faricimab and the vision gains as numerically greater, without reporting new numeric detail beyond what was disclosed in March. Ollin+1Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Scientific MeetingJul 13, 2026A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324NCT07484074
What it feeds
Ollin says it plans to start global Phase 3 trials of OLN324 in both DME and wAMD in the second half of 2026, recruiting across North America, South America, Europe, Japan, China and South Korea. OLN324 was discovered by and is being developed in collaboration with Innovent Biologics, which carries the compound internally as IBI324. The company describes OLN324 as engineered for higher Ang2 potency and higher molar dosing than faricimab, and higher molar dosing than aflibercept including Eylea HD, in a smaller protein format. Those design choices target the same VEGF and Ang2 pathway biology already validated by faricimab's approval, positioning OLN324 as a bridging entrant competing on potency and dosing rather than on a new mechanism. OllinOllin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Scientific MeetingJul 13, 2026
The competitive field
The broader DME and wAMD treatment landscape includes approved anti-VEGF agents such as faricimab, aflibercept and ranibizumab, plus later-stage programs spanning gene therapy, small molecules and other delivery formats, none of which share OLN324's VEGF/Ang2 bispecific mechanism in the comparator set surfaced here. No other trial in this set pairs a VEGF/Ang2 bispecific against faricimab in a randomized design, which leaves OLN324's head-to-head comparison structurally isolated within the mechanism it targets, even as the broader anti-VEGF class is well established clinically.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.